Evidence map›Paper›PMID 31884793›Full record

ArticleJournal of proteome research2020

Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.

Michael A Giacomantonio, Andra M Sterea, Youra Kim, Joao A Paulo, Derek R Clements, Barry E Kennedy, Moamen J Bydoun, Ge Shi, David M Waisman, Steven P Gygi and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of proteome research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Macrophages in immunoregulation and therapeutics.Signal transduction and targeted therapy · 2023
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Michael A GiacomantonioDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Andra M StereaDepartment of Microbiology and Immunology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Youra KimDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Joao A PauloDepartment of Cell Biology , Harvard Medical School , Boston , Massachusetts 02115-5730 , United States.
Derek R ClementsDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Barry E KennedyDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Moamen J BydounDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Ge ShiDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
David M WaismanDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Steven P GygiDepartment of Cell Biology , Harvard Medical School , Boston , Massachusetts 02115-5730 , United States.ORCID 0000-0001-7626-0034
Carman A GiacomantonioDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
J Patrick MurphyDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.
Shashi GujarDepartment of Pathology , Dalhousie University , Halifax , Nova Scotia B3H 4R2 , Canada.ORCID 0000-0002-5427-0829
Dalhousie University · CAHarvard University · US

Funding

New Sample Multiplexing Technologies to Identify Chemical Probes and Illuminate Ubiquitin BiologyR01GM067945 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GYGI, STEVEN P · 2003 to 2024
$10.5M
Advancing Multiplexed Isobaric Tag-based Strategies for Proteome ProfilingR01GM132129 · NIGMS · HARVARD MEDICAL SCHOOL · PI PAULO, JOAO A · 2019 to 2023
$1.7M
CIHRNIGMS NIH HHS R01 GM067945NIGMS NIH HHS R01 GM132129
6 · The paper itself

Abstract

The efficacy of oncolytic viruses (OVs), such as reovirus, is dictated by host immune responses, including those mediated by the pro- versus anti-inflammatory macrophages. As such, a detailed understanding of the interaction between reovirus and different macrophage types is critical for therapeutic efficacy. To explore reovirus-macrophage interactions, we performed tandem mass tag (TMT)-based quantitative temporal proteomics on mouse bone marrow-derived macrophages (BMMs) generated with two cytokines, macrophage colony stimulating factor (M-CSF) and granulocytic-macrophage colony stimulating factor (GM-CSF), representing anti- and proinflammatory macrophages, respectively. We quantified 6863 proteins across five time points in duplicate, comparing M-CSF (M-BMM) and GM-CSF (GM-BMM) in response to OV. We find that GM-BMMs have lower expression of key intrinsic proteins that facilitate an antiviral immune response, express higher levels of reovirus receptor protein JAM-A, and are more susceptible to oncolytic reovirus infection compared to M-BMMs. Interestingly, although M-BMMs are less susceptible to reovirus infection and subsequent cell death, they initiate an antireovirus adaptive T cell immune response comparable to that of GM-BMMs. Taken together, these data describe distinct proteome differences between these two macrophage populations in terms of their ability to mount antiviral immune responses.

Indexed as

Granulocyte-Macrophage Colony-Stimulating FactorMacrophage Colony-Stimulating FactorAnimalsBone MarrowBone Marrow CellsCells, CulturedMiceProteomeGranulocyte-Macrophage Colony-Stimulating FactorMacrophage Colony-Stimulating FactorProteomeantigen presentation/processingantiviral immune responsecell differentiationmacrophagesoncolytic virusesquantitative proteomicsreovirusviral defense

Identifiers

PMID31884793
PMCPMC7294930
OpenAlexW2996821602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.